BELLUS Health to Participate in Two Upcoming Healthcare Investor Conferences

first_img Previous articleIn Israel and beyond, virus vaccines bring political powerNext articleJuniper Research: Smart Traffic Management to Significantly Reduce Congestion and Emissions; Saving Cities $277 Billion by 2025 Digital AIM Web Support BELLUS Health to Participate in Two Upcoming Healthcare Investor Conferences WhatsApp TAGS  Facebook Twitter WhatsApp Twittercenter_img Pinterest LAVAL, Quebec–(BUSINESS WIRE)–Feb 22, 2021– BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced that Roberto Bellini, BELLUS Health’s President and Chief Executive Officer, will participate in two upcoming virtual healthcare investor conferences. Presentation Details: Event: Cowen 41st Annual Health Care Conference Format: Respiratory/infections panel discussion Date/Time: Monday, March 1, 2021 at 10:20 a.m. EST Event: H.C. Wainwright Global Life Sciences Conference Format: Prerecorded corporate presentation Date/Time: Available starting on Tuesday, March 9, 2021 at 7:00 a.m. EST An audio webcast from the H.C. Wainwright event may be accessed on the Events and Presentations page under the Investors & Media section of BELLUS Health’s website at www.bellushealth.com. Following the event, an archived webcast will be available on the Company’s website. About BELLUS Health (www.bellushealth.com) BELLUS Health is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders. The Company’s product candidate, BLU-5937, is being developed for the treatment of chronic cough and chronic pruritus. Chronic cough, the lead indication for BLU-5937, is a cough lasting more than eight weeks and is associated with significant adverse physical, social and psychosocial effects on health and quality of life. It is estimated that approximately 26 million adults in the United States suffer from chronic cough with approximately 3 million having refractory chronic cough lasting for more than a year and approximately 6 million having refractory chronic cough lasting more than 8 weeks and under one year. There is no specific therapy approved for refractory chronic cough and current treatment options are limited. Chronic pruritus, the second indication for BLU-5937, is commonly known as chronic itch and is an irritating sensation that leads to scratching and persists for longer than six weeks, which can be debilitating and can significantly impact quality of life. It is a hallmark of many inflammatory skin diseases, including atopic dermatitis (“AD”). It is estimated that AD afflicts approximately 5% of adults in the United States. Despite currently available treatments targeting AD, there continues to be a lack of options targeting the burden of pruritus in AD patients. View source version on businesswire.com:https://www.businesswire.com/news/home/20210222005269/en/ CONTACT: Danny Matthews Director, Investor Relations and Communications [email protected]: Julia Deutsch Solebury Trout [email protected] KEYWORD: UNITED STATES NORTH AMERICA CANADA INDUSTRY KEYWORD: BIOTECHNOLOGY GENERAL HEALTH HEALTH PHARMACEUTICAL CLINICAL TRIALS SOURCE: BELLUS Health Inc. Copyright Business Wire 2021. PUB: 02/22/2021 07:00 AM/DISC: 02/22/2021 07:01 AM http://www.businesswire.com/news/home/20210222005269/enCopyright Business Wire 2021. Facebook Pinterest Local NewsBusiness By Digital AIM Web Support – February 22, 2021 last_img

Posts Tagged with…

Write a Comment

Your email address will not be published. Required fields are marked *